A detailed history of Jpmorgan Chase & CO transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 355,747 shares of ABCL stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
355,747
Previous 334,264 6.43%
Holding current value
$1.04 Million
Previous $989,000 6.88%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$2.39 - $3.49 $51,344 - $74,975
21,483 Added 6.43%
355,747 $921,000
Q2 2024

Aug 12, 2024

SELL
$2.73 - $4.73 $99,647 - $172,649
-36,501 Reduced 9.84%
334,264 $989,000
Q1 2024

May 10, 2024

SELL
$4.29 - $5.97 $165,139 - $229,809
-38,494 Reduced 9.41%
370,765 $1.68 Million
Q4 2023

Feb 12, 2024

SELL
$3.91 - $5.93 $496,706 - $753,317
-127,035 Reduced 23.69%
409,259 $2.34 Million
Q3 2023

Nov 14, 2023

BUY
$4.6 - $7.95 $283,189 - $489,425
61,563 Added 12.97%
536,294 $2.47 Million
Q2 2023

Aug 11, 2023

SELL
$5.66 - $7.59 $1.34 Million - $1.8 Million
-236,555 Reduced 33.26%
474,731 $3.07 Million
Q1 2023

May 18, 2023

BUY
$7.31 - $11.18 $1.91 Million - $2.92 Million
260,934 Added 57.94%
711,286 $5.36 Million
Q1 2023

May 11, 2023

SELL
$7.31 - $11.18 $1.04 Million - $1.6 Million
-142,832 Reduced 24.08%
450,352 $3.4 Million
Q4 2022

Feb 13, 2023

BUY
$9.48 - $14.52 $882,151 - $1.35 Million
93,054 Added 18.61%
593,184 $6.01 Million
Q3 2022

Nov 14, 2022

BUY
$9.2 - $13.68 $828,239 - $1.23 Million
90,026 Added 21.95%
500,130 $4.95 Million
Q2 2022

Aug 11, 2022

BUY
$5.72 - $10.65 $1.48 Million - $2.76 Million
259,222 Added 171.8%
410,104 $4.37 Million
Q1 2022

May 11, 2022

BUY
$7.46 - $14.14 $513,576 - $973,454
68,844 Added 83.92%
150,882 $1.47 Million
Q4 2021

Feb 10, 2022

BUY
$12.99 - $17.73 $1.07 Million - $1.45 Million
82,038 New
82,038 $1.17 Million

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $833M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.